Screener
Arcus Biosciences RCUS Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Types of securities as of June 30, 2026 | Amortized Cost | Unrealized Gain | Unrealized Loss | Fair Value |
|---|---|---|---|---|
| Money market funds | $138 | — | — | $138 |
| U.S. treasury securities | 222 | — | — | 222 |
| Corporate securities and commercial paper | 407 | — | (1) | 406 |
| Certificate of deposit | 9 | — | — | 9 |
| Total cash, cash equivalents and marketable securities | $776 | — | $(1) | $775 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's unrealized gains on investments?
- Arcus Biosciences (RCUS) reported unrealized gains on investments of $0 in Q2 2026.
- What does unrealized gains on investments mean?
- The total unrealized gains on investments, typically related to available-for-sale securities.
Ask your AI about Arcus Biosciences's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude